Slide 1: Q3 2024 Earnings Call
Q3 2024 Earnings Call November 7, 2024
Slide 2: Forward Looking Statements
Forward Looking Statements Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans, or predictions of the future, are forward-looking statements within the meaning of the
Slide 3: Presenters
Jerrell Shelton Robert Stefanovich CEO - Cryoport CFO, SVP - Cryoport Mark Sawicki, Ph.D. Thomas Heinzen Chief Scientific Officer – Cryoport VP Investor Relations and and CEO - Cryoport Systems Corporate Development - Cryoport
Slide 4: Summary
Summary A leading global provider of supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract Business description research organizations (CRO's), developers, and researchers to carry out their r
Slide 5: Cryoport, Inc. Organization
Cryoport, Inc. Organization (NASDAQ: CYRX) © 2024 CRYOPORT, INC. 5
Slide 6: Cryoport – Q3 2024 Snapshot
Cryoport – Q3 2024 Snapshot Performance Global Platform (2) over 50 Facilities Globally $56.7 MM $225- $235 MM $272.7 MM in 17 Countries Q3-2024 Revenue FY 2024 Revenue Cash & Short-Term Guidance investments C> Supply Chain Leader Over 3,000+ Global Clients $6.1M 691 1,000+ Employees 17 11% of tot
Slide 7: Growing Cell & Gene Therapy Pipeline
Growing Cell & Gene Therapy Pipeline ✓691 clinical trials (net) in aggregate Clinical Trials Supported by Trial ✓ 79 Phase III trials in the Americas, EMEA and APAC Phase as of 9/30/24 Increased by 21 trials (net) over Q3 2023 Source: Company materials cross-referenced to clinical trial information
Slide 8: CGT Clinical Trials by Phase and Region
CGT Clinical Trials by Phase and Region © 2024 CRYOPORT, INC. 8
Slide 9: Cryoport Commercial Support
Cryoport Commercial Support – Now 17 AKUUGO® © 2024 CRYOPORT, INC. 9
Slide 10: Market Need
Market Need Drugs Approved by Scenario Patients Treated Per Year # of new therapies approved by FDA # of patients treated per year in trials or commercially approved CGT therapies (K) CAGR CAGR 120 96 ‘20-24 ‘25-27 500 100 79 39% 30% 72 450 Includes all potential patients Faster Rate + Trial Accel.
Slide 11: Global coverage and availability
CRYOPDP KEY FIGURES Global coverage and availability 16 Countries We operate in over 150 countries worldwide, with a global logistic network serving the Life Science industry, and together we serve 39 Facilities more than 3 million patients every year. Regions coverage: Over recent years, we have es
Slide 12: Our customers
CRYOPDP Our customers Specialized in Life Science and Healthcare industry. CROs & Laboratories Pharmaceutical Biotechnology Hospitals, Universities Other Ventures & Consultancy companies companies and other public entities (non health- related) © 2024 CRYOPORT, INC. 12
Slide 13: MVE's Product Family
MVE’s Product Family STAINLESS STEEL FREEZERS Ball Ground, GA Bulk storage stainless-steel freezers in a range of sizes and configurations Basic bulk storage stainless-steel freezer for the breeder market ALUMINUM DEWARS Chengdu, China Complete portfolio of aluminum dewars for sample storage, sample
Slide 14: Cryoport's Services Offering
Cryoport’s Services Offering © 2024 CRYOPORT, INC. 14
Slide 15: Cryoport's Logistics Management Made Easy
Cryoport’s Logistics Management Made Easy It’s as simple as a couple of clicks • Log into the Cryoportal® to create an order or select a prepopulated template • Carrier options, such as our Cryoshuttle®, integrators, and couriers or any combination to meet your specific shipment need are available •
Slide 16: Cryoport Systems Shipping Fleets
Cryoport Systems Shipping Fleets Advanced Therapy Shippers General Purpose Shippers © 2024 CRYOPORT, INC. 16
Slide 17: Continuous Vigilance to Minimize Risk and Maximize Success
Continuous Vigilance to Minimize Risk and Maximize Success Chain of Custody Chain of Condition Chain of Identity Traceability of the custody of Traceability of the condition of Traceability of the identity each client’s/patient's therapy each client’s/patient's therapy of each client’s/patient's the
Slide 18: IntegriCell Logistics Flow
IntegriCell Logistics Flow © 2024 CRYOPORT, INC. 18
Slide 19: A Unified Network Supporting the Life Sciences
A Unified Network Supporting the Life Sciences 17 countries > 50 locations US IE Brentwood, Tennessee Dublin Irvine, California PL Morris Plains, New Jersey Warsaw Houston, Texas San Antonio, Texas PH Ball Ground, Georgia Manila New Prague, Minnesota KR Valley Stream, New York Seoul Huntington Beach
Slide 20: Cryoport Revenue Drivers
Cryoport Revenue Drivers Services revenue 69% of total revenue in Q3 2024 Q3 2023 Revenue Q3 2024 Revenue Product Product 36% 31% Services Services 64% 69% © 2024 CRYOPORT, INC. 20
Slide 21: Cryoport Revenue Drivers
Cryoport Revenue Drivers Life Sciences Services Life Sciences Services Revenue Gross Margin ($ in millions) $39.3 46.0% +9% YoY 42.2% $36.0 +380 Bps Q3 2023 Q3 2024 Q3 2023 Q3 2024 © 2024 CRYOPORT, INC. 21
Slide 22: Cryoport Revenue Drivers
Cryoport Revenue Drivers BioLogistics Solutions Revenue BioStorage/BioServices Revenue ($ in millions) ($ in millions) $35.3 +9% YoY $4.0 +12% $32.5 YoY $3.5 Q3 2023 Q3 2024 Q3 2023 Q3 2024 © 2024 CRYOPORT, INC. 22
Slide 23: Capital Realignment Plan
Capital Realignment Plan Annualized cost reduction initiatives of approximately $22 million ©2024 CRYOPORT, INC. 23
Slide 24: Revenue by Type
Revenue by Type © 2024 CRYOPORT, INC. 24
Slide 25: Statement of Operations
Statement of Operations © 2024 CRYOPORT, INC. 25
Slide 26: Adjusted EBITDA
Adjusted EBITDA © 2024 CRYOPORT, INC. 26
Slide 27: Balance Sheet
Balance Sheet Cash and Investments: $272.7M © 2024 CRYOPORT, INC. 27
Slide 28: Upcoming Investor Conferences
Upcoming Investor Conferences Host Conference Date Location Global Healthcare Guggenheim November 11-13, 2024 Boston, MA Conference Global Healthcare Rancho Palos UBS November 11-14, 2024 Conference Verdes, CA NASH2024 Investment Stephens Conference November 19-20, 2024 Nashville, TN Conference Glob
Slide 29: Cryoport
O Cryoport Enabling the Future of Medicine . " , Me iS le — — ——